Table 3.
Outcome measures
| Study | Year | Type of treatment | Number of patients | Outcome measures | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||||
| Ibrahim et al. [8] | 2010 | ESWT | 25 | 7.9 | 92%†
(n = 25) |
61.70% | ||||
| Placebo | 25 | 1.3 (p < 0.001) |
4%†
(n = 25) (p < 0.001) |
15.8% (p < 0.001) |
||||||
| Gerdesmeyer et al. [6] | 2008 | ESWT | 125 | 56% (SD, 39.3%) | 60.98% (n = 125) |
60.8% (n = 125) |
60% (n = 125) |
52.85 (n = 125) |
58.4 % (n = 125) |
|
| Placebo | 118 | 44.1% (SD, 41.8%) (p = 0.0220) |
42.24% (n = 118) (p = 0.002) |
48.31% (n = 118) (p = 0.0269) |
40.68% (n = 118) (p = 0.0014) |
39.66 (n = 118) (p = 0.0216) |
41.52% (n = 118) (p = 0.0031) |
|||
| Marks et al. [11] | 2008 | ESWT | 16 | |||||||
| Placebo | 9 | |||||||||
| Gollwitzer et al. [7] | 2007 | ESWT | 20 | 73.2%* (n = 20) |
55%* (n = 20) |
55%* (n = 20) |
50%* (n = 20) |
60%‡
(n = 20) |
60% (n = 20) |
|
| Placebo | 20 | 40.5%* (n = 20) (p = 0.0302) |
40%* (n = 20) (p = 0.2148) |
30%* (n = 20) (p = 0.0648) |
40%* (n = 20) (p = 0.3057) |
35%‡
(n = 20) (p = 0.0769) |
40% (n = 20) (p = 0.0416) |
|||
| Malay et al. [10] | 2006 | ESWT | 115 | 3.39 (n = 112) |
||||||
| Placebo | 57 | 1.78 (n = 56) (p < 0.001) |
||||||||
| Rompe et al. [17] | 2003 | ESWT | 22 | |||||||
| Placebo | 23 | |||||||||
| Speed et al. [20] | 2003 | ESWT | 46 | |||||||
| Placebo | 42 | |||||||||
1 = improvement in mean VAS composite scores (heel pain in the morning, doing daily activities, and application of dolorimeter) from baseline or mean % improvement (SD) after 12 weeks; 2 = reduction in mean VAS score (points) from baseline in participants’ assessment of heel pain at 12 weeks; 3 = success rate of heel pain improvement (> 60% reduction in VAS scores) at 12 weeks for at least two of three heel pain monitoring criteria; 4 = success rate of heel pain (> 60% reduction in VAS scores) when taking first steps in morning at 12 weeks; 5 = success rate of heel pain (> 60% reduction in VAS scores) while doing daily activities at 12 weeks; 6 = success rate of heel pain (> 60% reduction in VAS scores) after application of the dolorimeter at 12 weeks; 7 = reduction in Roles and Maudsley scores (excellent to good) at 12 weeks; * % median change not % mean change; †only one VAS score used; ‡F-meter used rather than a dolorimeter.